UnknownNot Applicable

Anticoagulation Medicine in Surgical Repair for Total Anomalous Pulmonary Venous Connection

China150 participantsStarted 2020-02-20

Plain-language summary

Total anomalous pulmonary venous connection (TAPVC) is a complex congenital heart disease, requiring surgical repair. Pulmonary venous obstruction (PVO) is the major complication, with limited effective reinterventions and poor outcomes. This trial aims at investigating that postoperative anticoagulant management reduce the incidence of PVO.

Who can participate

Age range1 Year

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 1\. Infants and neonates who are diagnosed with TAPVC * 2\. Infants and neonates who undergo initial surgical repair for TAPVC Exclusion Criteria: * 1\. Concommitant diagnosis including functional single ventricular, double outlet right ventricle, tricuspid atresia, pulmonary atresia or transposition of the great arteries. * 2\. Older than 1-year-old.

What they're measuring

Incidence of postoperative pulmonary venous obstruction (PVO)

Timeframe: 2 years

Days of chest drainage

Timeframe: 2 years

Mortality rate

Timeframe: 2 years

Trial details

NCT IDNCT04241380

SponsorGuangdong Provincial People's Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-10-01

Contact for this trial

Rong Liufu, M.D.

020-83827812 liufurong103@163.com

View on ClinicalTrials.gov More Total Anomalous Pulmonary Venous Connection trials